We found a strong decrease in MAPT levels in response to X55, by more than 50%, in all X55-sensitive CDA-deficient tumor cells tested, whereas X55 treatment did not affect MAPT levels in X55-resistant CDA-deficient tumor cells (Fig. 4a and b and Supplementary Fig. 5a and b). The gene discussed is CDA; the disease is neoplasm.